Hannah Dzimitrowicz McManus
@hannahdzmd
Followers
447
Following
2K
Statuses
86
Genitourinary medical oncologist @DukeGUCancer
Durham, NC
Joined September 2018
RT @TiansterZhang: Fantastic recognition for @Daniel_J_George @DukeGUCancer — recipient of this year’s Vogelzang humanitarian award!! @Matt…
0
4
0
RT @AarmstrongDuke: Check out our podcast on treatment sequencing in mCRPC with @hannahdzmd based on this @pcan_jou…
0
4
0
Excited to share our new review on Navigating therapeutic sequencing in the metastatic castration-resistant prostate cancer patient journey. @AarmstrongDuke @CaPsurvivorship @TDorffOnc @sartor_oliver @nealshore @pcan_journal
2
3
20
Thank you @GUconference for the opportunity to share our work in @IRONMANregistry demonstrating the ability to adapt guideline concordant care for #prostatecancer in the real world. Fantastic conference for learning, networking, and fun! @IDEOlogyHealth
Great start to @GUconference with an interactive poster session. @hannahdzmd discussing high uptake of combined therapy for mHSPC in @IRONMANregistry @loreleimucci
0
1
18
RT @Daniel_J_George: Large @uk_biobank study confirmed many heritable gene-cancer associations. Shevach and @hannahdzmd explain how the new…
0
4
0
RT @DCockrellMD: Bittersweet last clinic day @UNCMedCenter after 10 years @UNC between college, residency, and fellowship. Seems like the r…
0
2
0
RT @TiansterZhang: The #WomeninOncology networking center has a wonderful line up at #ASCO24! Privileged to join @KVanLoonMD @SuzanneColeM…
0
9
0
At #AACR2024 ? Come check out our poster examining uptake of guideline concordant mHSPC care in @IRONMANregistry . Rapid uptake of changing therapies and 86% rate overall📈. Important to develop quality benchmarks to ensure #prostatecancer patients getting best therapies.
0
2
11
RT @TumorBoardTues: 1/4 🚨 Time for a #TumorBoardTuesday extra! @AarmstrongDuke discusses developments w PARPi from #GU24: - Sequence PARPi…
0
5
0
RT @AarmstrongDuke: Wondering what to offer your NEPC/small cell prostate cancer patient after platinum chemo? Clinical trials but also per…
0
5
0
RT @MattLabsMD: Awesome start to #GU24 sharing our clinical and implementation outcomes using pluvicto at @DukeGUCancer with rising ⭐️s Val…
0
3
0
@TumorBoardTues @AarmstrongDuke #PostTest Q2️⃣ #TumorBoardTuesday 👉🏽 Free CME 🔗 🧐 If, instead, this 66-year-old man with metastatic castrate resistance #prostatecancer had🧬CHEK2-mutated, but BRCA wild-type disease, what 1L treatment would you select❓
1
1
1